Clinical Trial Update: Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y [Phase 3]

View source ↗

Summary

A completed Phase 3 trial evaluated the immunogenicity and safety of an adjuvanted hepatitis B vaccine compared with Engerix-B in adults who did not respond to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Engerix-B (hepatitis B vaccine)
• HBV vaccine (adjuvanted) (Hepatitis B vaccine, adjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED